


# Multivariable analysis: A brief introduction

Chihaya Koriyama  
August 21<sup>th</sup>, 2019





# Why do we need multivariable analysis?

**“Treatment (control)”** for the confounding effects at analytical level


- ✓ Stratification by confounder(s)
- ✓ **Multivariable / multiple** analysis

**Prediction of individual risk**




# Regression models for multivariable analysis

| Paired? | Outcome variable                | Proper model                                        |
|---------|---------------------------------|-----------------------------------------------------|
| No      | Continuous                      | Linear regression model                             |
|         | Binomial                        | Logistic regression model                           |
|         | Categorical ( $\geq 3$ )        | Multinomial (polytomous) logistic regression model  |
|         | Binomial (event) with censoring | Cox proportional hazard model                       |
| Yes     | Continuous                      | Mixed effect model, Generalized estimating equation |
|         | Categorical ( $\geq 3$ )        | Generalized estimating equation                     |



# ***LINEAR REGRESSION ANALYSIS***

## Lung cancer mortality by daily cigarettes smoked




Original data: Doll and Hill Br Med J 1956





Number of obs = 32  
F(1, 30) = 726.87  
Prob > F = 0.0000  
R-squared = 0.9604  
Adj R-squared = 0.9590  
Root MSE = .75358

|        | ama | Coef.     | Std. Err. | t      | P> t  | [95% Conf. Interval] |
|--------|-----|-----------|-----------|--------|-------|----------------------|
| height |     | .4118029  | .0152743  | 26.96  | 0.000 | .3806086 .4429973    |
| _cons  |     | -42.82525 | 2.191352  | -19.54 | 0.000 | -47.30059 -38.34992  |

# Association between height and score of maths



## Both height and ability of maths increase with age



Age is a **confounding factor** in the association between height and ability of maths.







## How age itself influences the association between height and the ability of maths?

Let's see the equation

$$\text{Ability of maths (AM)} = \alpha + \beta_1(\text{Height})$$

$$\rightarrow \text{AM} = -42.8 + 0.41(\text{Height})$$

$$\text{AM} = \alpha + \beta_1(\text{Height}) + \beta_2(\text{Age})$$


$$\rightarrow \text{AM} = 1.48 - 0.01(\text{Height}) + 2.02(\text{Age})$$

Significant association between height and the ability of maths was gone after adjusting for the effect of age

| Source      | SS        | df | MS         | Number of obs = | 32     |
|-------------|-----------|----|------------|-----------------|--------|
| -----+----- |           |    |            | F(2, 29) =      | 851.23 |
| Model       | 422.6119  | 2  | 211.305972 | Prob > F =      | 0.0000 |
| Residual    | 7.19885   | 29 | .248236138 | R-squared =     | 0.9833 |
| -----+----- |           |    |            | Adj R-squared = | 0.9821 |
| Total       | 429.81079 | 31 | 13.8648643 | Root MSE =      | .49823 |

| ama             | Coef.            | Std. Err.       | t            | P> t         | [95% Conf. Interval] |                 |
|-----------------|------------------|-----------------|--------------|--------------|----------------------|-----------------|
| -----+-----     |                  |                 |              |              |                      |                 |
| <b>height  </b> | <b>-.0121303</b> | <b>.0680948</b> | <b>-0.18</b> | <b>0.860</b> | <b>-.1513998</b>     | <b>.1271393</b> |
| age             | 2.02461          | .3216095        | 6.30         | 0.000        | 1.366845             | 2.682375        |
| _cons           | 1.483038         | 7.185946        | 0.21         | 0.838        | -13.21387            | 16.17995        |
| -----+-----     |                  |                 |              |              |                      |                 |

No association between height and age-adjusted score of maths



# Interpretation of coefficients

Let's see the equation

$$\text{Ability of maths (AM)} = \alpha + \beta_1(\text{Height})$$

$$\rightarrow \text{AM} = -42.8 + 0.41(\text{Height})$$

0.41 points increase by 1cm increase of height

$$\text{AM} = \alpha + \beta_1(\text{Height}) + \beta_2(\text{Age})$$

$$\rightarrow \text{AM} = 1.48 - 0.01(\text{Height}) + 2.02(\text{Age})$$

0.01 points decrease by 1cm increase of height

Confounding effect: magnitude and direction of the association

## ANOVA table

Sum of Squares

Degrees of freedom

Mean sum of squares (SS/df)

F statistic (df<sub>m</sub>, df<sub>r</sub>)

P value of F test

| Source   | SS        | df | MS         |
|----------|-----------|----|------------|
| Model    | 422.6119  | 2  | 211.305972 |
| Residual | 7.19885   | 29 | .248236138 |
| Total    | 429.81079 | 31 | 13.8648643 |

Number of obs = 32  
 F(2, 29) = 851.23  
 Prob > F = 0.0000  
 R-squared = 0.9833  
 Adj R-squared = 0.9821  
 Root MSE = .49823

t = Coef. / SE

P value (H<sub>0</sub>: coef.=0)

| ama    | Coef.     | Std. Err. | t     | P> t  | [95% Conf. Interval] |
|--------|-----------|-----------|-------|-------|----------------------|
| height | -.0121303 | .0680948  | -0.18 | 0.860 | -.1513998 .1271393   |
| age    | 2.02461   | .3216095  | 6.30  | 0.000 | 1.366845 2.682375    |
| _cons  | 1.483038  | 7.185946  | 0.21  | 0.838 | -13.21387 16.17995   |

CI of Coef.



## Interpretation of coefficients in general

To simplify, the explanatory variable is binomial one: 1=exposed or 0=unexposed

Exposed:  $Y_e = \alpha + \beta(\text{Exp}=1) = \alpha + \beta$

Unexposed:  $Y_u = \alpha + \beta(\text{Exp}=0) = \alpha$

Difference:  $Y_e - Y_u = \beta$

■ **Coefficient estimate: difference in dependent value**



## Interpretation of coefficients after log-transformation of dependent variable

The explanatory variable is binomial one:  
1=exposed or 0=unexposed

Exposed:  $\ln(Y_e) = \alpha + \beta(\text{Exp}=1) = \alpha + \beta$

Unexposed:  $\ln(Y_u) = \alpha + \beta(\text{Exp}=0) = \alpha$

Difference:  $\ln(Y_e) - \ln(Y_u) = \beta$

**Ratio:**  $Y_e / Y_u = e^{\beta}$

- **Coefficient estimate: ratio of dependent value (after exponentiating)**

# Control of confounding with regression model

- Compared to **stratified analysis**, several confounding variables can be easily controlled simultaneously using a multivariable regression model.



- Results from the regression model are readily susceptible to bias if the model is not a good fit to the data.









Figure 12-4 Hypothetical example of a multivariable linear regression data involving a dichotomous exposure variable (exposed = solid circles, unexposed = open circles) and age.



Although the age distribution is not overlapped, a regression model will fit **two parallel straight lines** through the data.



***CORRELATION = REGRESSION ANALYSIS?***




# Correlation coefficient

- Strength of the **correlation** between two continuous variables ranging from -1 to 1
- **Correlation is a linear association** between two variables
- NOT to prove the causal association; x and y variable are interchangeable.


# Examples of correlation

$$r = 1$$



Positively correlated



$$r = -1$$




Negatively correlated

# What does “ $r=0$ ” mean?

- ~~■ No association between  $x$  and  $y$ ?~~
- No **linear** association between  $x$  and  $y$




# Correlation coefficient is not the magnitude of “slope”



線型が強い = 相関関係強い

Strong correlation



線型が弱い = 相関関係弱い

Weak correlation




# Correlation coefficients

- Pearson's CC ( $r$ ): parametric method
  - At least, one of the two variables should follow the normal distribution.
- Non-parametric methods
  - Spearman's CC ( $\rho$ )
  - Kendall's CC ( $\tau$ )



## r (correlation coefficient) and R-squared



$$r = 0.4481$$

$$0.4481 \times 0.4481 = ?$$


|               |   |        |
|---------------|---|--------|
| Number of obs | = | 759    |
| F(1, 757)     | = | 190.24 |
| Prob > F      | = | 0.0000 |
| R-squared     | = | 0.2008 |
| Adj R-squared | = | 0.1998 |
| Root MSE      | = | 5.4705 |

$$R^2 = r^2$$

R squared, **coefficient of determination**, is the proportion of the variance in the dependent variable that is predictable from the independent variable(s).

$$R^2 = 1 - \frac{\sum_i (y_i - \hat{y}_i)^2}{\sum_i (y_i - \bar{y})^2}$$

# r (correlation coefficient) and R-squared



|               |   |        |
|---------------|---|--------|
| Number of obs | = | 759    |
| F(1, 757)     | = | 190.24 |
| Prob > F      | = | 0.0000 |
| R-squared     | = | 0.2008 |
| Adj R-squared | = | 0.1998 |
| Root MSE      | = | 5.4705 |


Adjusted R squared value by the sample size and the number of variable(s)

Better to use when you have more variables or small sample size

$$W = -40 + 0.6084xH$$

The  $R^2$  coefficient of determination, ranging 0-1, is a statistical measure of **how well the regression predictions approximate** the real data points.

# r (correlation coefficient) and regression coefficient



$$r = 0.4481$$
$$P < 0.001$$

$$W = -40 + 0.6084 \times H$$

$$H = 133 + 0.3301 \times W$$

Regression  
coefficient

$$\sqrt{0.6084 \times 0.3301} = 0.4481$$



# ***ADJUSTMENT OF CORRELATION***

# Calculation skill and physical development

| weight | calculation |
|--------|-------------|
| 24.8   | 134         |
| 25.6   | 136         |
| 15.9   | 117         |
| 16.1   | 124         |
| 24.2   | 137         |
| 28.9   | 135         |
| 31.8   | 135         |
| 22.3   | 137         |
| 18.9   | 131         |
| 15     | 100         |

Is weight related  
to calculation  
skill?





## Estimation of age-adjusted correlation coefficient

- Correlation coefficient between weight and calculation skill was 0.79.
- Age is related to both variables, weight and calculation skill : age is a confounder.



partial correlation coefficient

-0.23 . . . after adjusting the effect of age



# Multivariate $\neq$ Multivariable (Multiple)

Am J Public Health. 2013 January; 103(1): 39–40.

Published online 2013 January. doi: [10.2105/AJPH.2012.300897](https://doi.org/10.2105/AJPH.2012.300897)

PMCID: PMC3518362

NIHMSID: [NIHMS514677](https://nihms.nih.gov/submitter/NIHMS514677)

## Multivariate or Multivariable Regression?

[Bertha Hidalgo](#), PhD, MPH<sup>✉</sup> and [Melody Goodman](#), PhD, MS

[Author information](#) ▶ [Article notes](#) ▶ [Copyright and License information](#) ▶

See letter "[Hidalgo and Goodman Respond](#)" in volume 10 on page e1.

This article has been [cited by](#) other articles in PMC.

## Abstract

Go to: ☐

The terms multivariate and multivariable are often used interchangeably in the public health literature. However, these terms actually represent 2 very distinct types of analyses. We define the 2 types of analysis and assess the prevalence of use of the statistical term multivariate in a 1-year span of articles published in the American Journal of Public Health. Our goal is to make a clear distinction and to identify the nuances that make these types of analyses so distinct from one another.



# Multivariable (Multiple) analysis

A multivariable model can be thought of as a model in which multiple variables are found on the right side of the model equation. This type of statistical model can be used to attempt to assess the relationship between a number of variables; one can assess independent relationships while adjusting for potential confounders.

This is the model to control the effects of confounders!

By contrast, a multivariable or multiple linear regression model would take the form

$$(2) y = \alpha + x_1\beta_1 + x_2\beta_2 + \dots + x_k\beta_k + \varepsilon$$

where  $y$  is a continuous dependent variable,  $x$  is a single predictor in the simple regression model, and  $x_1, x_2, \dots, x_k$  are the predictors in the multivariable model.

As is the case with linear models, logistic and proportional hazards regression models can be simple or multivariable. Each of these model structures has a single outcome variable and 1 or more independent or predictor variables.






# Multivariate analysis

Multivariate, by contrast, refers to the modeling of data that are often derived from longitudinal studies, wherein an outcome is measured for the same individual at multiple time points (repeated measures), or the modeling of nested/clustered data, wherein there are multiple individuals in each cluster. A multivariate linear regression model would have the form

$$(3) Y_{n \times p} = X_{n \times (k+1)} \beta_{(k+1) \times p} + \varepsilon$$

where the relationships between multiple dependent variables (i.e.,  $Y$ s)—measures of multiple outcomes—and a single set of predictor variables (i.e.,  $X$ s) are assessed.

This model is to analyze the relationship between “multiple outcomes” and a single set of predictors.



# ***LOGISTIC REGRESSION ANALYSIS***




# Logistic regression analysis


- Logistic regression is used to model the probability of a binary response as a function of a set of variables thought to possibly affect the response (called covariates).

$$Y = \begin{cases} 1: \text{case (with the disease)} \\ 0: \text{control (no disease)} \end{cases}$$

One could imagine trying to fit a linear model (since this is the simplest model !) for the probabilities, but often this leads to problems:



In a linear model, fitted probabilities can fall outside of 0 to 1. Because of this, linear models are seldom used to fit probabilities.



In a logistic regression analysis, the **logit** of the probability is modeled, rather than the probability itself.

$P$  = probability of getting disease ( $0 \sim 1$ )

$$\text{logit}(p) = \text{log} \left[ \frac{p}{1-p} \right]$$

This transformation allows us to use a linear model.

As always, we use the natural log.

The logit is therefore **the log odds**, since  $\text{odds} = p / (1-p)$

# Logistic regression model

Now, we have the same function with linear regression model in the right side.

$$\text{logit}(p_x) = \log \left[ \frac{p_x}{1 - p_x} \right] = \alpha + \beta x$$

where  $p_x$  = probability of event for a given value  $x$ , and  $\alpha$  and  $\beta$  are unknown parameters to be estimated from the data.

→ **Multivariable analysis** is applicable to adjust the effect of confounding factor.

## Interpretation of coefficients of logistic regression model

The explanatory variable is binomial one:  
1=exposed or 0=unexposed

Exposed:  $\log(O_e) = \alpha + \beta(\text{Exp}=1) = \alpha + \beta$

Unexposed:  $\log(O_u) = \alpha + \beta(\text{Exp}=0) = \alpha$

Difference:  $\log(O_e) - \log(O_u) = \beta$

**Odds ratio:**  $O_e / O_u = e^{\beta}$

■ **Coefficient estimate: Odds ratio (after exponentiating)**




# ***SURVIVAL ANALYSIS***







# Survival analysis

- **Survival time**: from the entry point (for example, when the treatment starts) until end point (for example, disease recurrence or the death from the disease)
- **Censoring**: the follow-up is stopped because of other reason (for example, study period is over or the death from other reason)






## Kaplan-Meier survival estimate



# Log-rank test:

Statistic test for the difference of survival probability



The statistic follows the chi-square distribution (df=1)

P=0.016



## Limitations of Kaplan-Meier method

- Mainly descriptive
- Doesn't control for covariates
- Requires categorical predictors
- Can't accommodate time-dependent variables

# Cox proportional hazard model



This model is expressed by the following formula;  $\lambda(t | x_1, \dots, x_k) = \lambda_0(t) \exp(\beta_0 + \beta_1 x_1 + \dots + \beta_k x_k)$  where  $\lambda(t)$  is the hazard of variable  $x_k$  and  $t$  is the time until the case is alive, and  $\lambda_0(t)$  is the baseline hazard. We assume that the log of hazard ratio is proportional to the variable  $X$ .

Log negative-log plot is useful to check

**Hazard ratio:**  $\lambda_1(t)/\lambda_0(t) = \exp(\beta)$

Exposed group

Un-exposed group



### Group A=1, Group B=0

No. of subjects = 22

No. of failures = 15

Time at risk = 77


Number of obs = 22

LR chi2(1) = 4.68

Prob > chi2 = 0.0305

Log likelihood = -35.943457

| _t | Haz. Ratio | Std. Err. | z     | P> z  | [95% Conf. Interval] |        |
|----|------------|-----------|-------|-------|----------------------|--------|
| A  | 0.29       | 0.1767    | -2.04 | 0.042 | 0.0895               | 0.9557 |







# ***STRATEGY FOR CONSTRUCTING REGRESSION MODELS***



# Basic principles

1. Stratified analysis should be first.
2. Determine which **confounders to include** in the model.
3. Estimate the shape of the exposure-disease relation.



## **Dose-response relation**

4. Evaluate **interaction**



## How to determine confounders: data-dependent manner



1. Start with a set of predictors of outcome based on the strength of their relation to the outcome.
2. Build a model by introducing predictor variables one at a time: check the amount of change in the coefficient of the exposure term  
> 10% change: include it as a confounder

## Example of a confounder (age)

Ability of maths (AM) =  $\alpha + \beta_1(\text{Height})$

→ AM = -42.8 + 0.41(Height)

> 10% change

AM =  $\alpha + \beta_1(\text{Height}) + \beta_2(\text{Age})$

→ AM = 1.48 - 0.01(Height) + 2.02 (Age)

## How to determine confounders: data-independent manner




Some researchers argue that  
“Without data analysis, decide  
confounders, important risk factors of  
the outcome, based on the previous  
studies.”

**How can we pick-up “important risk factors”?  
If there are few studies, how can we know  
confounders?**




# How many explanatory variables can we use in a model?

| Model                         | Number of explanatory variables            | Example                                                                                              |
|-------------------------------|--------------------------------------------|------------------------------------------------------------------------------------------------------|
| Linear regression model       | <b>Sample size / 15</b>                    | <u>Up to around 6-7 variables</u> in <b>100 subjects</b>                                             |
| Logistic regression model     | <b>Smaller sample size of outcome / 10</b> | <u>Up to 10 variables</u> if the numbers of cases and controls are <b>100</b> and 300, respectively. |
| Cox proportional hazard model | <b>The number of event / 10</b>            | <u>Up to 9 variables</u> if you have <b>90 events</b> out of 150 subjects                            |



# ATTENTION!

- When you include a categorical variable in your model, you have to count that as “the number of categories – 1”.
- For example, the variable of age group used in the previous practice, we have to count it as “two” (=3 categories -1) variables.



# ***PROPENSITY SCORE***



# If you cannot recruit enough sample size

- Calculate “**propensity score**” which can be used for adjustment of confounding effects.

## Example

### Aspirin Use and All-Cause Mortality Among Patients Being Evaluated for Known or Suspected Coronary Artery Disease

#### A Propensity Analysis

---

Patricia A. Gum, MD

---

Maran Thamilarasan, MD

---

Junko Watanabe, MD

---

Eugene H. Blackstone, MD

---

Michael S. Lauer, MD

**Context** Although aspirin has been shown to reduce cardiovascular morbidity and short-term mortality following acute myocardial infarction, the association between its use and long-term all-cause mortality has not been well defined.

**Objectives** To determine whether aspirin is associated with a mortality benefit in stable patients with known or suspected coronary disease and to identify patient characteristics that predict the maximum absolute mortality benefit from aspirin.

**Table 1.** Baseline and Exercise Characteristics According to Aspirin Use\*

| Variable                                            | Aspirin<br>(n = 2310) | No<br>Aspirin<br>(n = 3864) | P<br>Value |
|-----------------------------------------------------|-----------------------|-----------------------------|------------|
| Demographics                                        |                       |                             |            |
| Age, mean (SD), y                                   | 62 (11)               | 56 (12)                     | <.001      |
| Men, No. (%)                                        | 2167 (94)             | 2167 (56)                   | <.001      |
| Clinical history                                    |                       |                             |            |
| Diabetes, No. (%)                                   | 432 (19)              | 432 (11)                    | <.001      |
| Hypertension, No. (%)                               | 1569 (68)             | 1569 (41)                   | <.001      |
| Tobacco use, No. (%)                                | 500 (22)              | 500 (13)                    | .001       |
| Prior coronary artery disease, No. (%)              | 178 (8)               | 178 (20)                    | <.001      |
| Prior coronary artery bypass graft surgery, No. (%) | 21 (1)                | 21 (5)                      | <.001      |
| Prior percutaneous coronary intervention, No. (%)   | 667 (29)              | 148 (4)                     | <.001      |
| Prior Q-wave MI, No. (%)                            | 369 (16)              | 285 (7)                     | <.001      |
| Atrial fibrillation, No. (%)                        | 27 (1)                | 55 (1)                      | .04        |
| Congestive heart failure, No. (%)                   | 127 (6)               | 178 (5)                     | .12        |
| Medication use                                      |                       |                             |            |
| Digoxin use, No. (%)                                | 171 (7)               | 216 (6)                     | .004       |
| $\beta$ -Blocker use, No. (%)                       | 811 (35)              | 550 (14)                    | <.001      |
| Diltiazem/verapamil use, No. (%)                    | 452 (20)              | 405 (10)                    | <.001      |
| Nifedipine use, No. (%)                             | 261 (11)              | 283 (7)                     | <.001      |
| Lipid-lowering therapy, No. (%)                     | 775 (34)              | 380 (10)                    | <.001      |
| ACE inhibitor use, No. (%)                          | 349 (15)              | 441 (11)                    | <.001      |
| Cardiovascular assessment and exercise capacity     |                       |                             |            |
| Body mass index, mean (SD), kg/m <sup>2</sup>       | 29 (5)                | 30 (7)                      | <.001      |
| Ejection fraction, mean (SD), %                     | 50 (9)                | 53 (7)                      | <.001      |
| Resting heart rate, mean (SD), beats/min            | 74 (13)               | 79 (14)                     | <.001      |
| Resting blood pressure, mean (SD), mm Hg            | 130 (14)              | 130 (14)                    | .92        |

Almost all prognostic factors (n=28) are related to aspirin use!

After **matching by propensity score**, the distribution of prognostic factors are similar between aspirin users and non-users.

**Table 3.** Selected Baseline and Exercise Characteristics According to Aspirin Use In Propensity Matched Cohort

|                                                   | Aspirin<br>(n = 1351) | No<br>Aspirin<br>(n = 1351) | P<br>Value |
|---------------------------------------------------|-----------------------|-----------------------------|------------|
| Demographics                                      |                       |                             |            |
| Age, mean (SD), y                                 | 60 (11)               | 61 (11)                     | .16        |
| Men, No. (%)                                      | 951 (70)              | 974 (72)                    | .33        |
| Clinical history                                  |                       |                             |            |
| Diabetes, No. (%)                                 | 203 (15)              | 207 (15)                    | .83        |
| Hypertension, No. (%)                             | 679 (50)              | 698 (52)                    | .46        |
| Tobacco use, No. (%)                              | 161 (12)              | 162 (12)                    | .95        |
| Cardiac variables                                 |                       |                             |            |
| Prior coronary artery disease, No. (%)            | 652 (48)              | 659 (49)                    | .79        |
| Prior coronary artery bypass graft, No. (%)       | 251 (19)              | 235 (17)                    | .42        |
| Prior percutaneous coronary intervention, No. (%) | 166 (12)              | 147 (11)                    | .25        |
| Prior Q-wave MI, No. (%)                          | 194 (14)              | 206 (15)                    | .52        |
| Atrial fibrillation, No. (%)                      | 21 (2)                | 24 (2)                      | .65        |
| Congestive heart failure, No. (%)                 | 79 (6)                | 89 (7)                      | .43        |

It is just like a RCT!  
(pseud RCT)

**Table 4.** Cox Proportional Hazards Analyses of Aspirin Use and Mortality Among Propensity-Matched Patients (n = 2702)\*

| Model                                           | Hazard Ratio (95% CI) | P Value |
|-------------------------------------------------|-----------------------|---------|
| Unadjusted                                      | 0.53 (0.38-0.74)      | .002    |
| Adjusted for propensity                         | 0.53 (0.38-0.74)      | <.001   |
| Adjusted for propensity and selected variables† | 0.59 (0.42-0.83)      | .002    |
| Adjusted for propensity and all covariates‡     | 0.56 (0.40-0.78)      | <.001   |

\*CI indicates confidence interval.


†Selected variables included prior coronary artery disease, prior coronary artery bypass grafting, prior percutaneous intervention, and ejection fraction  $\leq 40\%$ .

‡For a list of covariates, see Table 2 footnote (†).

You need to include only propensity score in the model.



**WE SHOULD NOT RELY ON  
P VALUE TOO MUCH**



## Statistic significance vs. Clinical significance

Statistic significance  $\neq$  Clinical significance

- P value(s) do NOT tell us the significance in clinical practice / biological importance.
- If your sample size is quite large, you may obtain a result with statistic significance.  
So what?

## ***RCT of donepezil for Alzheimer's disease***

Lancet. 2004 Jun 26;363(9427):2105-15.

**Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.**

Courtney CJ, Farrell D, Gray R, Hills P, Lynch J, Sallwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lander C, Shaw H, Bentham P; AD2000 Collaborative Group.

⊕ Auth

**Abstract**

**BACKG**

determin

psycholo

**METHOD**

allocated donepezil (5 mg/

double-blind treatment co

defined by loss of either

assessments were sought

**FINDINGS:** Cognition averaged 0.8 MMSE

points better (0.5-1.6; p<0.0001) with

institutionalisation (42% vs 44% at 3 ye

care in the donepezil group compared

institutional care was 0.96 (95% CI 0.7

and psychological symptoms, carer psy

donepezil.

**INTERPRETATION:** Donepezil is not cost effective, with benefits below minimally relevant thresholds. More effective treatments than cholinesterase inhibitors are needed for Alzheimer's disease.

Cognition averaged 0.8 MMSE points better (95%CI 0.5-1.2; p<0.0001) and functionality 1.0 BADLS points (0.5-1.6; p<0.0001) with donepezil over the first 2 years.


Donepezil is **not** cost effective, with benefits below minimally relevant thresholds. More effective treatments than cholinesterase inhibitors are needed for AD.



## Which description is appropriate?

- In a RCT study, the mortality rates of **new** drug A and **old** drug B were 30% and 20%, respectively. And, the p value was 0.6 for the difference of them.
  1. The mortality rate of drug A is equivalent to that of drug B.
  2. We cannot say “there is a difference in the mortality between drug A and B”.
  3. We cannot say “the mortality of drug A is higher than that of drug B”.





## We cannot tell the equivalence by p value

- In the previous example, the sample size of each arm was 10.
- The result tells us “you failed to reject the null hypothesis because of small sample size”.
  - 293 subjects for each arm are required.
- The difference of mortality rate is 10% and its 95% CI is -30%, 50%.



# **American Statistical Association Releases Statement on Statistical Significance and P-values**

Provides Principles to Improve the Conduct and Interpretation of Quantitative Science

<https://www.amstat.org/newsroom/pressreleases/P-ValueStatement.pdf>

1. P-values can indicate how incompatible the data are with a specified statistical model.
2. P-values do not measure the probability that the studied hypothesis is true, or the probability that the data were produced by random chance alone.
3. Scientific conclusions and business or policy decisions should not be based only on whether a p-value passes a specific threshold.
4. Proper inference requires full reporting and transparency.
5. A p-value, or statistical significance, does not measure the size of an effect or the importance of a result.
6. By itself, a p-value does not provide a good measure of evidence regarding a model or hypothesis.